Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Any Solid Tumors Progressed After a Prior Immunotherapy: early-phase trial registry

1 of 1 indexed Any Solid Tumors Progressed After a Prior Immunotherapy trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Any Solid Tumors Progressed After a Prior Immunotherapy: 1 US clinical trial tracked, 1 recruiting.

Any Solid Tumors Progressed After a Prior Immunotherapy is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is VM Oncology, running 1 of these trials.

Enrollment posture brief

Registry condition any-solid-tumors-progressed-after-a-prior-immunotherapy

OPEN 1 | RECR 100% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Any Solid Tumors Progres (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Any Solid Tumors Progressed After a Prior Immunotherapy

Any Solid Tumors Progressed After a Prior Immunotherapy lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Any Solid Tumors Progressed After a Prior Immunotherapy on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Any Solid Tumors Progressed After a Prior Immunotherapy is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 11

Phase Distribution

PhaseTrial count
Phase 1 1

Top Sponsors

VM Oncology 1 trials

Named interventions

Most-linked intervention names on Any Solid Tumors Progressed After a Prior Immunotherapy records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

VMD-928 Tablet and Pembrolizumab (200 mg) Drug
1 trials
VMD-928 100 mg Tablet Drug
1 trials

US sites by state

Facility locations filed on Any Solid Tumors Progressed After a Prior Immunotherapy trials. A trial with sites in several states counts in each.

Utah 1 trials
Texas 1 trials
Pennsylvania 1 trials
Ohio 1 trials
New York 1 trials
New Mexico 1 trials
New Jersey 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Any Solid Tumors Progressed After a Prior Immunotherapy page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Any Solid Tumors Progressed After a Prior Immunotherapy trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • VM Oncology sponsors the most Any Solid Tumors Progressed After a Prior Immunotherapy trials on record, review their full trial history before evaluating a specific study. See VM Oncology's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Any Solid Tumors Progressed After a Prior Immunotherapy condition card totals 1 registered trials; most-linked intervention VMD-928 Tablet and Pembrolizumab (200 mg); top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.